BR112018006025A2 - composição farmacêutica e aplicação da mesma - Google Patents

composição farmacêutica e aplicação da mesma

Info

Publication number
BR112018006025A2
BR112018006025A2 BR112018006025-9A BR112018006025A BR112018006025A2 BR 112018006025 A2 BR112018006025 A2 BR 112018006025A2 BR 112018006025 A BR112018006025 A BR 112018006025A BR 112018006025 A2 BR112018006025 A2 BR 112018006025A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
application
same
cocrystal
stereoisomer
Prior art date
Application number
BR112018006025-9A
Other languages
English (en)
Chinese (zh)
Other versions
BR112018006025B1 (pt
Inventor
Ge Chuansheng
Liao Baisong
Lee Wen-Cherng
Original Assignee
Kangpu Biopharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangpu Biopharmaceuticals, Ltd. filed Critical Kangpu Biopharmaceuticals, Ltd.
Publication of BR112018006025A2 publication Critical patent/BR112018006025A2/pt
Publication of BR112018006025B1 publication Critical patent/BR112018006025B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

uma composição farmacêutica e uma aplicação da mesma são descritas. a composição farmacêutica inclui um ou mais de um composto benzo-heterocíclico como mostrado na fórmula (i), um sal farmaceuticamente aceitável da mesma, um solvato da mesma, uma forma cristalina da mesma, um cocristal da mesma, um estereoisômero da mesma, um composto de isótopo da mesma, um metabólito da mesma e um profármaco da mesma, e um modulador de via de receptor de androgênio. a composição farmacêutica inibe melhor o crescimento de célula de câncer de próstata.
BR112018006025-9A 2015-09-29 2016-09-28 Composição farmacêutica e aplicação da mesma BR112018006025B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510631654 2015-09-29
CN201510631654.9 2015-09-29
PCT/CN2016/100642 WO2017054739A1 (zh) 2015-09-29 2016-09-28 一种药物组合物及其应用

Publications (2)

Publication Number Publication Date
BR112018006025A2 true BR112018006025A2 (pt) 2018-10-09
BR112018006025B1 BR112018006025B1 (pt) 2023-12-05

Family

ID=58418383

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006025-9A BR112018006025B1 (pt) 2015-09-29 2016-09-28 Composição farmacêutica e aplicação da mesma

Country Status (16)

Country Link
US (3) US20180271849A1 (pt)
EP (1) EP3357513B1 (pt)
JP (1) JP6633744B2 (pt)
KR (1) KR102053556B1 (pt)
CN (1) CN106551934B (pt)
AU (1) AU2016332236B2 (pt)
BR (1) BR112018006025B1 (pt)
CA (1) CA3000547C (pt)
DK (1) DK3357513T3 (pt)
ES (1) ES2963446T3 (pt)
HK (1) HK1251153A1 (pt)
NZ (1) NZ742001A (pt)
PL (1) PL3357513T3 (pt)
RU (1) RU2705576C2 (pt)
WO (1) WO2017054739A1 (pt)
ZA (1) ZA201802125B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3453759B1 (en) * 2016-01-29 2023-08-30 Kyoto University Platelet production promoter and method of producing platelets using same
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US10806719B2 (en) * 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3527210B1 (en) 2016-12-16 2021-06-09 Kangpu Biopharmaceuticals, Ltd. Combined composition comprising a benzoheterocyclic compound and an androgen receptor pathway modulator and uses thereof
ES2899372T3 (es) * 2017-02-13 2022-03-11 Kangpu Biopharmaceuticals Ltd Combinación de tratamiento del cáncer de próstata, composición farmacéutica y método de tratamiento
HUE064340T2 (hu) 2018-04-23 2024-03-28 Celgene Corp Szubsztituált 4-aminoizoindolin-1,3-dion-származékok és alkalmazásuk limfóma kezelésére
WO2020205608A1 (en) * 2019-03-29 2020-10-08 Emory University Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
JP2023522040A (ja) * 2020-04-17 2023-05-26 エッサ ファーマ，インコーポレイテッド Ｎ末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用
CN113440533B (zh) * 2021-07-01 2022-02-01 江南大学 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用
CN113855797B (zh) * 2021-11-19 2023-11-10 安徽科技学院 一种兽用免疫疫苗的稀释剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20140011774A1 (en) * 2002-12-05 2014-01-09 University Of Tennessee Research Foundation Selective androgen receptor modulators
UA94964C2 (ru) * 2006-09-26 2011-06-25 Селджин Корпорэйшн Производные 5-замещенного хиназолинона, композиция, которая их содержит, и их применение
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
US20120071554A1 (en) * 2008-10-28 2012-03-22 Liu Julie F Deuterated 2-propylpentanoic acid compounds
EP2396313A1 (en) * 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of thalidomide
EP2396312A1 (en) * 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
WO2011050962A1 (en) * 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
WO2011100380A1 (en) * 2010-02-11 2011-08-18 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2014152833A1 (en) * 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
KR102191256B1 (ko) * 2014-10-30 2020-12-15 강푸 바이오파마슈티칼즈 리미티드 이소인돌린 유도체, 이의 중간체, 제조방법, 약물 조성물 및 응용

Also Published As

Publication number Publication date
DK3357513T3 (da) 2023-11-27
AU2016332236A8 (en) 2018-06-14
EP3357513B1 (en) 2023-10-25
KR102053556B1 (ko) 2020-01-08
AU2016332236A1 (en) 2018-05-17
US20240173312A1 (en) 2024-05-30
KR20180054840A (ko) 2018-05-24
CA3000547A1 (en) 2017-04-06
JP6633744B2 (ja) 2020-01-22
EP3357513A1 (en) 2018-08-08
EP3357513A4 (en) 2018-08-29
RU2018115037A3 (pt) 2019-10-25
NZ742001A (en) 2019-06-28
JP2018530555A (ja) 2018-10-18
BR112018006025B1 (pt) 2023-12-05
AU2016332236B2 (en) 2019-04-11
RU2018115037A (ru) 2019-10-25
CN106551934A (zh) 2017-04-05
PL3357513T3 (pl) 2024-04-02
WO2017054739A1 (zh) 2017-04-06
HK1251153A1 (zh) 2019-01-25
ES2963446T3 (es) 2024-03-27
CN106551934B (zh) 2020-09-11
ZA201802125B (en) 2022-11-30
RU2705576C2 (ru) 2019-11-08
US20180271849A1 (en) 2018-09-27
CA3000547C (en) 2021-03-23
US20210113545A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
BR112018006025A2 (pt) composição farmacêutica e aplicação da mesma
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
UY36275A (es) Compuestos aminopirimidinilo
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
TR201906325T4 (tr) Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri.
CL2018000529A1 (es) Compuestos heteroarilo y su uso como fármacos terapéuticos.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
JO3742B1 (ar) مركب بيرانو داي بيريدين
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
BR112018073368A2 (pt) sal farmaceuticamente aceitável como inibidor de canal de potássio da medula renal externa
ECSP18023544A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1
IN2013MU03309A (pt)
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/09/2016, OBSERVADAS AS CONDICOES LEGAIS